NAMA
RXRX icon

Nikko Asset Management Americas’s Recursion Pharmaceuticals RXRX Stock Holding History

Nikko Asset Management Americas’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.2M Buy
5,511,687
+92,466
+2% +$308K 0.26% 72
2026
Q1 		$16.6M Sell
5,419,221
-801,804
-13% -$3.1M 0.23% 71
2025
Q4 		$25.4M Sell
6,221,025
-1,244,833
-17% -$6.17M 0.29% 67
2025
Q3 		$36.4M Sell
7,465,858
-701,887
-9% -$3.69M 0.35% 62
2025
Q2 		$41.2M Sell
8,167,745
-239,589
-3% -$1.18M 0.41% 51
2025
Q1 		$44.4M Sell
8,407,334
-501,317
-6% -$3.65M 0.57% 46
2024
Q4 		$60.1M Sell
8,908,651
-786,127
-8% -$5.29M 0.65% 40
2024
Q3 		$63.9M Sell
9,694,778
-239,713
-2% -$1.72M 0.72% 38
2024
Q2 		$74.3M Sell
9,934,491
-428,312
-4% -$3.74M 0.86% 31
2024
Q1 		$103M Buy
10,362,803
+1,159,023
+13% +$12.9M 1.02% 29
2023
Q4 		$90.6M Buy
9,203,780
+5,680,656
+161% +$40.5M 0.87% 31
2023
Q3 		$27M Buy
3,523,124
+2,685,724
+321% +$26.8M 0.32% 55
2023
Q2 		$6.25M Buy
837,400
+335,423
+67% +$2.35M 0.07% 105
2023
Q1 		$3.3M Buy
501,977
+47,455
+10% +$376K 0.04% 126
2022
Q4 		$3.5M Sell
454,522
-36,218
-7% -$355K 0.05% 126
2022
Q3 		$5.16M Buy
490,740
+90,839
+23% +$920K 0.07% 112
2022
Q2 		$3.24M Sell
399,901
-15,367
-4% -$103K 0.04% 137
2022
Q1 		$2.82M Buy
415,268
+46,274
+13% +$492K 0.02% 152
2021
Q4 		$6.32M Sell
368,994
-40,200
-10% -$756K 0.03% 128
2021
Q3 		$8.59M Buy
409,194
+173,348
+74% +$4.91M 0.04% 127
2021
Q2 		$8.61M Buy
+235,846
New +$6.98M 0.03% 136

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Nikko Asset Management Americas's RXRX Position: Q2 2026 in Review

Nikko Asset Management Americas increased its Recursion Pharmaceuticals (RXRX) stake by 1.7% in Q2 2026, buying an estimated $308K and bringing the position to 5,511,687 shares worth $20.2M. The position accounts for 0.26% of the portfolio, ranked #72.

Nikko Asset Management Americas first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $103M in Q1 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Nikko Asset Management Americas held 5,511,687 shares of Recursion Pharmaceuticals worth $20.2M as of Q2 2026.
  • Nikko Asset Management Americas bought 92,466 Recursion Pharmaceuticals shares in Q2 2026, an estimated $308K.
  • Recursion Pharmaceuticals made up 0.26% of Nikko Asset Management Americas's portfolio in Q2 2026, its #72 holding.
  • Nikko Asset Management Americas first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Nikko Asset Management Americas's Recursion Pharmaceuticals position peaked at $103M in Q1 2024.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Nikko Asset Management Americas's 13F filing for Q2 2026, filed 13 Aug 2026.